|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM08354223X |
| 003 |
DE-627 |
| 005 |
20250130065523.0 |
| 007 |
tu |
| 008 |
231222s1993 xx ||||| 00| ||jpn c |
| 028 |
5 |
2 |
|a pubmed25n0279.xml
|
| 035 |
|
|
|a (DE-627)NLM08354223X
|
| 035 |
|
|
|a (NLM)8379483
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a jpn
|
| 100 |
1 |
|
|a Shiono, A
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Clinical evaluation of Augpenin (clavulanic acid-ticarcillin) in urinary tract infections
|b especially against beta-lactamase producing strains
|
| 264 |
|
1 |
|c 1993
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 20.10.1993
|
| 500 |
|
|
|a Date Revised 20.11.2014
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Augpenin contains ticarcillin (TIPC) and clavulanic acid (CVA), at a ratio of 15:1. The beta-lactamase inhibitor, CVA, has been added to protect the TIPC from inactivation by beta-lactamase. To investigate the drug efficacy and safety against urinary tract infections (UTI), Augpenin was administered to 33 patients with chronic complicated UTI and 7 patients with acute pyelonephritis. Thirty two cases were evaluable by the UTI criteria. Excellent results were obtained in 6 of the cases of acute pyelonephritis, and moderate results in 1 case, with an overall effectiveness rate of 100%. Excellent results were obtained in 14 of the cases of chronic complicated UTI, moderate results in 9 cases, and poor results in 2 cases, with an overall effectiveness rate of 92%. No adverse reactions were noted, but a transient elevation of glutamic oxaloacetic transaminase and glutamic pyruvic transaminase levels was observed in 2 cases
|
| 650 |
|
4 |
|a English Abstract
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Clavulanic Acids
|2 NLM
|
| 650 |
|
7 |
|a beta-Lactamase Inhibitors
|2 NLM
|
| 650 |
|
7 |
|a Clavulanic Acid
|2 NLM
|
| 650 |
|
7 |
|a 23521W1S24
|2 NLM
|
| 650 |
|
7 |
|a beta-Lactamases
|2 NLM
|
| 650 |
|
7 |
|a EC 3.5.2.6
|2 NLM
|
| 650 |
|
7 |
|a Ticarcillin
|2 NLM
|
| 650 |
|
7 |
|a F93UJX4SWT
|2 NLM
|
| 700 |
1 |
|
|a Kurihara, J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hayashi, M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Suzuki, T
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Imai, K
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yamanaka, H
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Takezawa, Y
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kiren, H
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Okabe, K
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tomaru, Y
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Hinyokika kiyo. Acta urologica Japonica
|d 1962
|g 39(1993), 8 vom: 15. Aug., Seite 777-82
|w (DE-627)NLM012631779
|x 0018-1994
|7 nnns
|
| 773 |
1 |
8 |
|g volume:39
|g year:1993
|g number:8
|g day:15
|g month:08
|g pages:777-82
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_2001
|
| 912 |
|
|
|a GBV_ILN_2003
|
| 912 |
|
|
|a GBV_ILN_2005
|
| 912 |
|
|
|a GBV_ILN_2006
|
| 912 |
|
|
|a GBV_ILN_2008
|
| 912 |
|
|
|a GBV_ILN_2010
|
| 912 |
|
|
|a GBV_ILN_2012
|
| 912 |
|
|
|a GBV_ILN_2018
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 39
|j 1993
|e 8
|b 15
|c 08
|h 777-82
|